Oncosil Medical Osake

Oncosil Medical EBIT per osake

EBIT per osake yhtiöstä Oncosil Medical (OSL.AX) 22.8.2026 päivämäärällä on −1,37 AUD. Edellisenä vuonna EBIT per osake oli −2,15 AUD — muutos −36,11 % (korkeampi).

EBIT per osake

−1,37AUD

YoY

−36,11%

Viimeksi päivitetty:

EBIT per osake yhtiöstä Oncosil Medical on 2026 −1,37 AUD. EBIT per osake yhtiöstä Oncosil Medical oli 2025 −2,15 AUD. Se laskee −36,11% korkeampi edelliseen vuoteen verrattuna.

Oncosil Medical EBIT per osake historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

EBIT per osake
Date
EBIT per osake
1.1.2020
−2,01 AUD
1.1.2021
−3,88 AUD
1.1.2022
−4,00 AUD
1.1.2023
−3,77 AUD
1.1.2024
−2,15 AUD
1.1.2025
−1,37 AUD
1.1.2026 (e)
−0,85 AUD
1.1.2027 (e)
0,00 AUD
Oncosil Medical EBIT per osake historia
VUOSIEBIT per osakeYoY
est0,00AUD−100,00%
est−0,85AUD−37,88%
−1,37AUD−36,11%
−2,15AUD−43,03%
−3,77AUD−5,76%
−4,00AUD+3,19%
−3,88AUD+93,27%
−2,01AUD−50,58%
−4,06AUD−17,14%
−4,90AUD+9,94%
−4,46AUD+21,83%
−3,66AUD+66,23%
−2,20AUD−18,12%
−2,69AUD+27,79%
−2,10AUD+145,00%
−0,86AUD−37,10%
−1,36AUD−834,49%
0,19AUD−108,89%
−2,09AUD−85,03%
−13,96AUD+20,22%
−11,61AUD+1 039,90%
−1,02AUD
Access this data via the Eulerpool API

Oncosil Medical Osakeanalyysi

Mitä Oncosil Medical tekee? Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option. Oncosil Medical on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Oncosil Medical osakkeesta

Yhtiön Oncosil Medical EBIT per osake on −1,37 AUD vuonna 2026.

EBIT per osake yhtiöstä Oncosil Medical muuttui arvosta −2,15 AUD arvoon −1,37 AUD, mikä edustaa −36,11 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBIT per osake Oncosil Medical:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBIT per osake mittaa operatiivisen voiton, joka on kohdistettu kullekin ulkona olevalle osakkeelle.

Access this data via the Eulerpool API

Tuloslaskelma — Oncosil Medical

Kaikki tunnusluvut — Oncosil Medical